Sparks commentary - Cantargia

Healthcare

Sparks - Cantargia

More on this equity
Cantargia (OMX: CANTA) enrols first patient in leukaemia study
Published by Arron Aatkar, PhD

Cantargia has confirmed that the first patient has been in enrolled in the study assessing nadunolimab in leukaemia. More specifically, this is an investigator-initiated, open-label, Phase Ib/IIa clinical trial designed to evaluate safety and efficacy following treatment with nadunolimab and chemotherapy in 40 participants with either acute myeloid leukaemia (n=20) or myelodysplastic syndrome (n=20). Full recruitment is anticipated from 2027.

Latest

Healthcare | Comment

Cantargia (OMX: CANTA) breast cancer study fully recruited

Industrials | Comment

NWF (LON: NWF) acquires Northern Energy Oil

Healthcare | Comment

Cantargia (OMX: CANTA) reports positive CAN10 update

Subscribe to Edison

Get access to the very latest content matched to your personal investment style.

Sign up for free